16 17 Patients with cancer may report neuropsychiatric abnormalities including cognitive impairment, behavioral 18 disturbances, and psychiatric disorders that potentially worsen their quality of life, reduce their treatment response, 19 and aggravate their overall prognosis. Neuropsychiatric disturbances have a different pathophysiology, including 20 immuno-inflammatory and neuroendocrine mechanisms, as a consequence of oncologic treatments (chemo-and radio-21 therapy). Among clinicians involved in the management of such patients, psychiatrists need to pay particular attention 22 in recognizing behavioral disturbances that arise in oncologic patients, and determining those that may be effectively 23 treated with psychotropic medications, psychotherapeutic interventions, and an integration of them. Through the 24 contribution of different clinicians actively involved in the management of oncological patients, the present review is 25 ultimately aimed at updating psychiatrists in relation to the pathophysiological mechanisms responsible for the onset of 26 cognitive, affective, and behavioral syndromes in these patients, along with epidemiologic and clinical considerations 27 and therapeutic perspectives.
withdrawal, anorexia, increased slow-wave sleep, cognitive 84 alterations, and increased pain sensitivity). 4 Bouchard 85 et al 5 examined the relationship between depressive 86 symptoms and inflammation in women with early-stage 87 breast cancer. They found that depression correlated with 88 increased levels of proinflammatory cytokines such as 89 IL-1β and IL-6 and, in particular, with higher levels of 90 TNF-α. In addition, cytokine administration in patients 91 with melanoma frequently induced depressive symptoms, 92 including suicidal ideation. 6 93 An interesting finding was that immune system 94 activation resulting from the systemic administration of 95 IL-2 and IFN-α to cancer patients decreased plasma 96 tryptophan levels, and this reduction correlated with 97 the depressive symptoms. 7 Decreased tryptophan could 98 be due to the activation (mediated by pro inflammatory 99 cytokines, including IFN-γ and TNF-α) of enzymes 100 involved in tryptophan degradation. 8 Since tryptofan 101 is the precursor of the neurotransmitter 5-hydroxy- 102 tryptamine (serotonin), a decreased tryptophan bioavail- 103 ability can lead to decreased serotonin synthesis. 104 Increased tryptophan catabolism has been found in 105 several malignancies. 9-11 106 The pathophysiological mechanisms of paraneoplastic 107 syndromes have been also associated with the presence of 108 either intracellular (anti-Hu, anti-Yo, anti-Ma, and Cv2/ 109 CRMP5) or neuronal-surface (NMDAR, AMPAR, and 110 GABA b R) antibodies. 12 In the first case, because the targets 111 are deeply located within cells, is thought that T-cell 112 cytotoxicity is a key mechanism underlying the neuronal Depression SCLC: small cell lung cancer; TGCT: testicular germ cell tumor; * adenocarcinoma, large-cell carcinoma, and pleural metastasis of adenocarcinoma; § breast, parotid gland, ovary, colon, kidney, lymphoma, and extragonadalchoriocarcinoma; ‡ patients who developed pancreatic cancer following the mental illness designation). Incidence is in accordance with data reported by GLOBOCAN 2012. 22 Along this view, an intriguing and less known body of 141 research concerns the association between pancreatic cancer 142 and alterations in mood possibly due to multiple mechan- 143 isms. 35 Depression, anxiety, and suicidal thoughts often 144 precede or accompany the diagnosis. Moreover, depression 145 often occurs before clinical diagnosis; in addition, in later 146 stages of disease, mood disorders are more pronounced in 147 patients with pancreatic cancer than in those with other 148 abdominal tumors. 21, 36 However, the pathophysiology of 149 this correlation remains largely unknown, possibly compris-150 ing tumor-induced changes in the neuroendocrine and acid-151 base systems. 37 In particular, IL-6 over-expression that is 152 induced by pancreatic cancer is known to down-regulate the 153 synthesis of dopamine and norepinephrine, thus interfering 154 with the HPA axis. In addition, pancreatic cancer cells might 155 secrete antibodies that directly block serotonin receptors or 156 reduce their synaptic availability in the central nervous 157 system (CNS). 38, 39 158 Neuroimaging 159 Morphological magnetic resonance imaging (MRI) is 160 normal in most cases, with the exception of anti-NMDAR 161 encephalitis, for which approximately 50% of patients 162 show T2 or FLAIR signal hyperintensity in the hippo-163 campus, cerebellar or cerebral cortex, frontobasal and 164 insular regions, and, occasionally, the spinal cord. 165 The findings are usually mild or transient and can be 166 accompanied by contrast enhancement in the meninges. 28 
167
In depressed patients with cancer, brain increased 168 inflammation, as reflected by plasma C-reactive protein 169 and inflammatory cytokine levels, was associated with 170 decreased brain connectivity studied with MRI within 171 reward-related brain regions. 40 Table 2 ). Paraneoplastic limbic encephalitis 44 is characterized by 202 a subacute (days to several weeks) appearance of confusion 203 and memory loss with an inability to remember new 204 information due to dysfunction of the mesial temporal lobe 205 (particularly the hippocampus), behavioral changes, and 206 psychiatric symptoms (including depression, agitation and 207 psychosis, aggression, and compulsive behavior); the latter 208 symptoms are very common and often predominate, 209 especially during the early stages of disease. Altered 210 cognition may fluctuate, and the level of consciousness 211 often declines progressively to coma. Recurrent temporal 212 seizures are frequent and sometimes progress to status 213 epilepticus. When neuronal damage derives from inflam-214 mation and necrosis (classic limbic encephalitis with 215 intracellular antibodies), prognosis is usually poor and 216 depends on the extension of cerebral lesions; on the 217 contrary, synaptic interference mediated by cell-surface 218 antibodies is reversible so that neuronal damage is limited 219 and, if treated, anti-NMDA encephalitis has generally a 220 better outcome. 46 
221
Wernicke's encephalopathy is a severe neuropsychiatric 222 syndrome due to thiamine (Vitamin B1) deficiency, usually 223 observed in malnourished alcoholics. It is characterized by 224 a triad of signs including eye movement disorders, 225 cerebellar dysfunctions (ataxia or gait instability), and 226 altered mental status. Disorientation in time and space, 227 confusion, impaired memory, and decreased attention are 228 often described, sometimes evolving to severe and irrever-229 sible memory deficit with confabulation (Korsakoff's 230 syndrome). Cancer patients are at risk of vitamin 231 deficiency for many reasons: thiamine intake could be 232 insufficient due to malnutrition, nausea, vomiting, or 233 prolonged parenteral nutrition; gastrointestinal surgery 234 may induce malabsorption through the loss gastrointest-235 inal surface. 47 A prompt administration of thiamine can 236 lead to excellent clinical improvement. 58 Small improvements were described, but these 295 findings require confirmation using larger and more 296 conclusive trials. 297 Nonpharmacological approaches enhance cognitive 298 performance and perceived cognitive functioning. 59 299 Rehabilitation programs include direct cognitive rehabi-300 litation or compensatory training that addresses execu-301 tive functioning and attention, processing speed, 302 working and long-term memory, and visual-spatial skills. 303 Most studies have shown significant improvements in 304 objective and subjective cognitive performance and in 305 quality of life in patients undergoing rehabilitation. 306 Treated patients also showed better improvement in 307 non-trained skills and better managed other psychologi-308 cal symptoms, such as anxiety, depression, and fatigue, 309 and improved sleep quality. 60 Cognitive training appears 310 to be the most effective for groups and individuals. 59 311 However, coping strategies such as cognitive-behavioral 312 therapy (CBT) 60 or restorative and mindfulness-based 313 stress reduction programs 61 have been proposed to 314 improve cognitive functions, and encouraging results 315 emerged. Some improvements were reported with 316 physical exercise 62 and yoga practice, 63 but these studies 317 involved small sample sizes and different types of 318 exercise programs. 319 Affective and Behavioral Changes 320 Patients with cancer are particularly vulnerable to the 321 development of behavioral alterations and psychiatric 322 disorders, which may in turn affect the course and 323 outcome of the primary oncologic disease. 64 Therefore, 324 to implement the appropriate therapeutic intervention, 325 it is important to establish a psychopathological 326 diagnosis by differentiating expected emotional reac-327 tions from isolated symptoms (eg, anger or irritability) 328 and syndromes (eg, adjustment disorders or major 329 depressive disorder). Another distinct syndrome to take into consideration 375 when assessing depression is demoralization, which has 376 been described as a specific and different condition of 377 existential distress in individuals at the end of their life. 378 Patients describe feelings of hopelessness and/or help-379 lessness, which are often related to the experience of a 380 loss of meaning in life. Certain symptoms may overlap 381 with major depression. Demoralization in the medically 382 ill population recently showed prevalence rates ranging 383 from 20.6% to 33.3% of cases. 72 Anxiety disorders have 384 been variably associated with the diagnosis and treat-385 ment of cancer, and their prevalence can paradoxically 386 increase after the treatment of cancer is concluded, 387 because patients may feel more vulnerable. 73 The 388 prevalence of posttraumatic stress disorder (PTSD) in 389 cancer patients ranges from 5% to 19%. 74
390
The lifetime prevalence rates of affective disorders 391 in patients with ovarian and prostate cancers in pre-, 392 during-, and post-treatment settings range from 8% to 393 27%. 75, 76 Patients with head and neck cancer were found 394 to show the highest rates of major depressive disorder 395 among oncological patients, with an incidence of 396 15%-50%. 77 Previously, depression has been strongly 397 associated with oropharyngeal (22%-57%), pancreatic 398 (33%-50%), breast (1.5%-46%), and lung (11%-44%) 399 cancer, with lower rates in in patients affected by other 400 forms of cancer, such as colon (13%-25%) and gyneco-401 logical (12%-23%) cancers and lymphoma (8%-19%). 78
402
In terms of prognosis, evidence showing that depression 403 is responsible for significant suffering and distress, reduces 404 participation in medical care, and can prolong the hospital 405 stay needs to be particularly taken into account. 79,80 406 The suicide incidence in cancer was found to be 407 approximately double that in the general population. 81 408 Diagnoses specifically associated with higher suicide 409 rates include prostate, lung, pancreatic, head, and neck 410 cancers, with the first year after diagnosis carrying a 411 higher risk for suicide. 81 ing. 94 Neuropathic pain may benefit from adjuvant 443 treatment with selective serotonin norepinephrine reup-444 take inhibitors (SNRIs), low-dose tricyclic antidepressants, 445 and SSRIs. 95, 96 An effective psychopharmacological inte-446 grated treatment is mandatory in cancer patients given the 447 evidence that untreated psychiatric comorbidity is asso- 455 of certain antineoplastic drugs. Among the former, for 456 instance, several antipsychotics were shown to increase 457 serum prolactin, and hyperprolactinemia has been linked, 458 in turn, to the development of mammary gland tumors in 459 animal studies. 98 If, in these cases, second generation 460 antipsychotics should be preferred to neuroleptics, none-461 theless, more studies and updated recommendations from 462 treatment guidelines are needed to assess pros and cons of 463 undertreatment of serious psychiatric disorders in patients 464 with cancer, based on unproven contraindications to 465 psychiatric medications. 99 
466
Another noteworthy issue is represented by the 467 interaction that some antineoplastic drugs may have 468 with psychotropic drugs that interfere with cytocrome 469 P450 (CYP). One of the most studied cases in the field is 470 represented by tamoxifen, an adjuvant hormonal therapy 471 that is widely used for estrogen receptor positive 472 metastatic breast cancer. Given that tamoxifen is 473 metabolized to its more active form (endoxifen) by 474 CYP2D6, decreases in CYP2D6 activity due to interac-475 tions with psychotropic drugs that inhibit it 476 (eg, paroxetine and fluoxetine) may reduce the activity 477 of tamoxifen and confer an increased risk of recur-478 rence. 100 If, in such contexts, psychotropic drugs that 479 do not interfere with the activity of CYP2D6 should 480 be preferred, recent data in the field have assessed the 481 available evidence in a more balanced way, 101 recom-482 mending caution and considering clinical aspects that 483 vary from case to case. 484 Over the last several years, novel approaches for the 485 management of behavioral alterations in patients with 486 cancer have been proposed and examined. Among these, 487 ketamine-a dissociative anesthetic psychotropic com-488 pound-has been tested in oncologic patients with Table 4 ). The design of these studies FAC: 5-fluorouracil, doxorubicin, and cyclophosphamide; FEC: 5-fluorouracil, epirubicin, and cyclophosphamide; CTC: cyclophosphamide, thiotepa, and carboplatin; DCP: doxorubicin, cyclophosphamide, and paclitaxel; AAT: androgen ablation therapy; § RT in combination with CT. 520 with cytotoxic agents showed a cognitive decline relative 521 to their pre-treatment cognitive status and to breast 522 cancer patients without chemotherapy and non-cancer 523 controls over the same period. 54, 55, 107, 108 Specific drugs 524 may have different effects. Fluorouracil can induce 525 hyperammonemia, 109 thus causing hyperammonemic 526 encephalopathy, whose clinical manifestations range 527 from psychomotor slowing and flapping tremor to 528 severe consciousness disturbances. 110 Also, luteinizing 529 hormone-releasing hormone (LHRH) agonists are asso-530 ciated with non-nonsteroidal antiandrogens to obtain a 531 combined androgen blockage, 111,112 and this treatment 532 can cause neurological disturbances such as visuomotor 533 slowing, slowed reaction times, and impaired working 534 memory. [113] [114] [115] 535 Several trials found a correlation between cognitive 536 dysfunction and chemotherapy in women with non-537 metastatic breast tumors. 48, 50, 105, 106, 116 This association 538 is termed "chemobrain." In women receiving a regimen of 539 5-fluorouracil, doxorubicin, and cyclophosphamide, Wefel 540 et al 50 showed that approximately 60% of patients 541 experienced a cognitive decline with decreased attention, 542 learning, and processing speed, thus suggesting a disrup-543 tion in frontal network systems. Interestingly, many 544 patients improved 1 year after completing 5-fluorouracil, 545 doxorubicin, and cyclophosphamide (FAC) therapy, 546 especially when work-related abilities were tested. In this 547 context, it is worth noting that before the initiation of 548 systemic adjuvant therapy, women with breast cancer 549 exhibited declines in a wide range of cognitive functions, 550 involving verbal learning, nonverbal memory, confronta-551 tional naming, complex visuoconstruction, and fine motor 552 dexterity. 116 Women treated with tamoxifen for breast 553 cancer have lower brain concentrations of myo-inositol. 124 554 Tamoxifen induces areas of hypometabolism in the inferior 555 and dorsal lateral frontal lobes and decreases right 556 hippocampal volumes. 125
557
The irradiation of head and neck tumors (in particular 558 cancer of the nasopharynx and paranasal sinuses) 559 might cause radiation-induced vascular damage in the 560 medial temporal lobe, thus affecting memory. Irradiation 561 triggers an inflammatory response with endothelial 562 injury. 126 Paulino et al 120 reported intellectual and 563 academic delays in 3 out of 30 children who had received 564 megavoltage radiotherapy for head and neck rhabdomyo-565 sarcoma. A moderate general developmental delay 566 including pronounced motor deficits that were asso-567 ciated with various levels of perceptual and cognitive 568 problems was observed in all children treated with total 569 brain irradiation prior to bone marrow transplanta-570 tion. 127 Cognitive impairment accompanying radiother-571 apy has also been reported after the irradiation of body 572 regions that are distant from the brain, in particular for 573 non-metastatic breast cancer treatment, 121,122,128,129 574 possibly by increasing levels of IL-6. 123 Radiation dose, 575 site of primary tumor, and the timing of association with 576 chemotherapy (CT) are variable (Table 4) 
